Charles River Laboratories International, Inc. $CRL Stake Lessened by Hsbc Holdings PLC

Hsbc Holdings PLC lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 25.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,084 shares of the medical research company’s stock after selling 20,876 shares during the quarter. Hsbc Holdings PLC’s holdings in Charles River Laboratories International were worth $12,401,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Jones Financial Companies Lllp increased its position in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC bought a new position in Charles River Laboratories International during the first quarter valued at about $418,000. American Century Companies Inc. grew its holdings in Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after acquiring an additional 1,616 shares during the period. Brown Advisory Inc. grew its holdings in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after acquiring an additional 114 shares during the period. Finally, California Public Employees Retirement System raised its position in Charles River Laboratories International by 3.9% in the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after acquiring an additional 3,198 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CRL shares. Weiss Ratings downgraded shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their target price for the company from $167.00 to $219.00 in a research note on Friday, May 29th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Mizuho set a $192.00 price objective on Charles River Laboratories International in a research report on Friday, May 8th. Finally, Evercore restated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Stock Up 5.2%

Shares of NYSE:CRL opened at $212.66 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The company has a market cap of $10.24 billion, a PE ratio of -56.56, a price-to-earnings-growth ratio of 2.31 and a beta of 1.46. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $228.88. The firm has a 50 day simple moving average of $176.29 and a 200 day simple moving average of $183.13.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the previous year, the company posted $2.34 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.